Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Williamson

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
Menopause (New York, N.Y.)|November 7, 2013
A standardized exercise intervention differentially affects premenopausal and postmenopausal African-American womenJan Kretzschmar, Dianne M Babbitt, Keith M Diaz, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
International Journal of Hypertension|May 22, 2013
Endothelial activation microparticles and inflammation status improve with exercise training in african americansDianne M Babbitt, Keith M Diaz, Deborah L Feairheller, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 1, 2014
Effects of moderate aerobic exercise training on vascular health and blood pressure in African AmericansDeborah L Feairheller, Keith M Diaz, Mohammed A Kashem, et al.
Bone Marrow Transplantation|November 9, 2010
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATGS El Kourashy, T Williamson, M A Chaudhry, et al.
Nature Communications|December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B CellsElizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, et al.
Cell Reports|March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell LinesJames Campbell, Colm J Ryan, Rachel Brough, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
Menopause (New York, N.Y.)|November 7, 2013
A standardized exercise intervention differentially affects premenopausal and postmenopausal African-American womenJan Kretzschmar, Dianne M Babbitt, Keith M Diaz, et al.
Molecular Cancer Therapeutics|June 17, 2017
Modeling Therapy Resistance in <i>BRCA1/2</i>-Mutant CancersAmy Dréan, Chris T Williamson, Rachel Brough, et al.
International Journal of Hypertension|May 22, 2013
Endothelial activation microparticles and inflammation status improve with exercise training in african americansDianne M Babbitt, Keith M Diaz, Deborah L Feairheller, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|May 1, 2014
Effects of moderate aerobic exercise training on vascular health and blood pressure in African AmericansDeborah L Feairheller, Keith M Diaz, Mohammed A Kashem, et al.
Bone Marrow Transplantation|November 9, 2010
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATGS El Kourashy, T Williamson, M A Chaudhry, et al.
Nature Communications|December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1AChris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Cancer Research|October 18, 2017
ATR Is a Therapeutic Target in Synovial SarcomaSamuel E Jones, Emmy D G Fleuren, Jessica Frankum, et al.
Molecular Cancer Therapeutics|July 2, 2016
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with DasatinibRowan E Miller, Rachel Brough, Ilirjana Bajrami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B CellsElizabeth A Lemm, Beatriz Valle-Argos, Lindsay D Smith, et al.
Cell Reports|March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell LinesJames Campbell, Colm J Ryan, Rachel Brough, et al.
Pageof 19